|
|
|
| Effect of L-carnitine combined with Erythropoietin and Iron Sucrose in the treatment of uremia with hemodialysis and renal anemia |
| GUO Dong-ci ZHANG Bao-tong |
| Hemodialysis Room,Liaoyang Central Hospital |
|
|
|
|
Abstract Objective To explore the effect of L-carnitine combined with Erythropoietin and Iron Sucrose in the treatment of uremia with hemodialysis and renal anemia patients.Methods From April 2018 to June 2019,84 patients with uremia who were admitted to Liaoyang Central Hospital for hemodialysis with renal anemia were selected as the research subjects and divided into the conventional group (42 cases) and the observation group (42 cases) according to the random number table method.Patients i n the conventional group were treated with Erythropoietin combined with Iron Sucrose,and patients in the observation group were treated with L-carnitine on the basis of the treatment in the convent ional group.The total effective rate of clinical treatment,hemoglobin (Hb),hematocrit (HCT),ferritin (SF),transferrin saturation (TSAT) levels,amount of Erythropoietin,and incid ence of adverse reactions between the two groups were compared.Results The total effective rate of treatment in the observation group was 97.62% (41/42),which was higher than 85.71% (36/42) in the conventional group,and the difference was statistically significant (P＜0.05).After 2,4,and 6 weeks of treatment,the levels of Hb,HCT,SF,and TSAT in the observation group were higher than those in the conventional group,and the differences were statistically significant (P＜0.05).After 4 and 6 weeks of treatment,the amount of Erythropoietin in the observation group was less than that in the conventional group,and the difference was statistically significant (P＜0.05).The total incidence of adverse reactions in the observation group was lower than that in the routine group,and the diff erence was statistically significant (P＜0.05).Conclusion L-carnitine combined with Erythropoietin and Iron Sucrose in the treatment of patients with uremia and hemodialysis with renal ane mia can effectively improve the Hb and HCT levels of the patients,and thus improve the prognosis,with significant clinical value.
|
|
|
|
|
|
| [11] |
李昌艳，刘娟，顾芳，等.静脉输注蔗糖铁联合重组人促红细胞生成素 对维持血液透析肾性贫血患者的疗效与安全性分析[J].解放军医药杂志，2020，32（2）：51-55.
|
| [13] |
夏季平，袁发焕，冯兵，等.左卡尼汀对血液透析患者红细胞变形性和膜稳定性的效应[J].重庆医学，2008，37（22）：2594-2595，2597.
|
| [14] |
吴利杰，董发.左卡尼汀治疗慢性心力衰竭患者的疗效及安全性[J].实用临床医药杂志，2020，24（2）：104-107.
|
| [4] |
中华中医药学会肾病分会.慢性肾衰竭的诊断、辨证分型及疗效评定（试行方案）[J].上海中医药杂志，2006，40（8）：8-9.
|
| [5] |
陆再英，钟南山.内科学[M].7版.北京：人民卫生出版社，2009：259-263.
|
| [6] |
郭光英，姚丽.锌对慢性肾脏病保护作用的研究进展[J].中华肾脏病杂志，2019，35（11）：861-865.
|
| [8] |
汪杨，魏日胞.慢性肾脏病肾性贫血的基础与临床研究现状及进展[J].中国中西医结合肾病杂志，2019，20（5）：452-455.
|
| [10] |
王莹.静脉铁剂与口服铁剂纠正血液透析/腹膜透析患者贫血的研究[J].首都食品与医药，2019，26（5）：66.
|
| [7] |
Liakopoulos V，Roumeliotis S，Bozikas A，et al.Antioxidant Supplementation in Renal Replacement Therapy Patients：Is There Evidence?[J].Oxid Med Cell Longev，2019，2019：9109 473.
|
| [9] |
张晶，张承英.抗EPO 抗体特性、分类及其相关纯红细胞再生障碍性贫血的发病机制及诊治进展[J].武警医学，2018，29（12）：1169-1172.
|
| [12] |
Liakopoulos V，Roumeliotis S，Zarogiannis S，et al.Oxidative stress in hemodialysis：causative mechanisms，clinical implications，and possible therapeutic interventions[J].Seminars in Dialysis，2018，32（1）：58-71.
|
| [15] |
石海燕，蔡婷，赵婷.促红细胞生成素联合左卡尼汀对血液透析肾性贫血患者的临床疗效[J].上海医药，2019，40（19）：20-22.
|
| [16] |
马遥，孙晓丹，彭彦平，等.EPO 联合左卡尼汀对老年尿毒症透析患者营养状态及生活质量的影响[J].中国医师杂志，2020，22（1）：116-119.
|
| [1] |
江伟，高玉娟.促红细胞生成素在多种贫血中的临床意义[J].临床与病理杂志，2020，40（1）：153-156.
|
| [2] |
侯静，温向琼，刘进，等.左卡尼汀和蔗糖铁对老年血液透析患者肾性贫血及氧化应激的影响[J].中国老年学杂志，2015，35（5）：1184-1186.
|
| [3] |
唐文哲，王忠玲，王雪娇，等.左卡尼汀对老年维持性血液透析患者微炎症、营养不良和贫血的影响[J].湖南师范大学学报（医学版），2019，16（4）：83-86.
|
| [17] |
杨波.左卡尼汀对PNS 的疗效及对脂代谢和氧化应激指标的影响[J].西南国防医药，2019，29（1）：30-33.
|
| [18] |
占晗琳.左卡尼汀联合血液透析治疗尿毒症性周围神经病变的临床效果[J].中国当代 医药，2019，26（7）：108-110
|
| [19] |
黄军悦，马志刚，李莹屏，等.高通量血液透析联合左卡尼汀对尿毒症患者血脂代谢的影响[J].临床荟萃，2019，34（3）：253-256.
|
| [20] |
岳丽红，王海涛，刘颖，邱琳琳.医院-社区-家庭联合干预对维持性血液透析患者贫血状态的影响[J].中国临床研究，2020，33（3）：429-432.
|
| [21] |
张丽萍.左卡尼汀联合前列地尔治疗糖尿病肾病临床疗效及安全性分析[J].中国现代医生，2019，57（15）：46-48.
|
|
|
|
